Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
View Patent ↗The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata ( L. operculata ), S. officinale ( V. sabadilla ), and Galphimia Glauca ( G. glauca ) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata ( L. operculata ) 10% extract MT, S. officinale ( V. sabadilla ) 3× extract, and Galphimia Glauca ( G. glauca ) 10% extract MT in a pharmaceutically acceptable carrier.
1. A method for treating a common cold caused by Rhinovirus infection, said method comprising: nasally administering to a human in need thereof a therapeutically effective amount of a composition comprising: (a) from about 0.001 wt. % to about 0.5 wt. % of a mixture of L. operculata 10 wt. % extract (MT), S. officinale 3× extract and G. glauca 10 wt. % extract (MT); (b) from about 0.5 wt. % to about 1.5 wt. % of a cellulosic thickener; (c) from about 0.01 wt. % to about 1 wt. % of a surfactant; (d) from about 0.1 wt. % to about 1 wt. % of an organic acid; (e) from about 0.1 to about 2 wt. % of at least one alkaline material; (f) from about 0.001 wt. % to about 1 wt. % of an inhalant selected from the group consisting of eucalyptol, eugenol, menthol, camphor, and mixtures thereof; (g) from about 0.05 wt. % to about 0.5 wt. % of an amino acid; (h) from about 0.1 wt. % to about 1 wt. % sodium chloride; and (i) from about 90 wt. % to about 99 wt. % water, wherein each wt. % is based on the total weight of the composition.
2. The method according to claim 1 , wherein said cellulosic thickener is hypromellose.
3. The method according to claim 1 , wherein said surfactant is polysorbate 80.
4. The method according to claim 1 , wherein said organic acid is succinic acid.
5. The method according to claim 1 , wherein said at least one alkaline material is a mixture of sodium monobasic and sodium dibasic phosphate salts.
6. The method according to claim 1 , wherein said inhalant is a mixture of eucalyptol, eugenol and menthol.
7. The method according to claim 1 , wherein said amino acid is selected from the group consisting of glycine, L-lysine, and mixtures thereof.
8. The method according to claim 1 , wherein said composition further comprises 2-phenylethanol at a level of about 0.001 wt. % to about 1 wt. %, based on the total weight of the composition.
9. The method according to claim 1 , wherein said composition further comprises at least one drug active.
10. The method according to claim 1 , wherein said therapeutically effective amount comprises from about 50 μL to about 250 μL of said composition administered twice in each nostril of the human in need of treatment thereof, 5 times daily, approximately every 3 hours during waking hours, for 6 days.